Dementia Treatment Market – Global Industry Analysis and Forecast (2023-2029)


Dementia Treatment Market was valued US$ 14.92 Bn in 2022 and is expected to reach US$ 26.11 Bn by 2029 at a 8.32% CAGR, during a forecast period.

Dementia Treatment Market Dynamics

Dementia covers a wide range of diseases and condition characterized by decline in memory, language, also comprising Alzheimer’s disease, which is most common cause of dementia. Disorders clustered below the common term “dementia” are affected by abnormal brain conditions. Dementia is a condition characterized by a deterioration in memory, language, problem-solving and other thinking skills that affect a person's capability to accomplish everyday activities. Alzheimer's is the most common cause of dementia.Dementia Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The scope of the report includes a detailed study of global and regional markets for Dementia Treatment with the reasons given for variants in the growth of the industry in certain regions.

Increase in R&D expenditure, raised frequency of Alzheimer’s across the globe, surged geriatric population, upsurge in awareness about neurodegenerative diseases in emerging countries, and rich pipeline of new treatment alternatives are projected to lift the dementia treatment market throughout the forecast period. Additionally, rising research and development activities in disease transforming drugs and increase in investment by key players in clinical studies of innovative treatment options are anticipated to drive the dementia treatment market during forecast period. Nevertheless, the increased cost of innovative treatments and severe adverse effects concomitant with certain treatments are anticipated to hamper the dementia treatment market.

Dementia Treatment Market Segment Analysis

The report on dementia treatment market covers segments such as Drug Class, Distribution Channel and Region. The Drug Class segment includes Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combined Drug and Others. Among the Drug Class, Cholinergic/ Cholinesterase (ChE) Inhibitors is accounted for the largest xx% market share in the dementia treatment market. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Retail Pharmacies, and Online Sales. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest xx% market share in the Dementia Treatment Market.

Dementia Treatment Market Regional Insights

Based on regional segment, the global Dementia Treatment Market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America leads the dementia treatment market due to high awareness concerning Alzheimer’s disease in the U.S. and increased frequency of Alzheimer’s disease in the region. As per the World Alzheimer’s Report, Alzheimer’s is the sixth-leading reason of death in the U.S. and presently, more than x Mn Americans are reported Alzheimer’s. Increasing prevalence of Alzheimer’s in elderly age group and demand for innovative therapies and disease transforming drugs is a key factor driving the market in North America. European market demonstrated similar pattern and followed North America dementia treatment market. The market in Asia Pacific is estimated to enlarge at a considerably high CAGR throughout the forecast period, due to developing health care infrastructure and increasing awareness concerning Alzheimer’s in countries like China and India.

Key players operating in the Dementia Treatment Market are Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc. Pfizer, Inc., Daiichi Sankyo Company, Ltd., Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. The companies functioning in the market are concentrating on R&D investments and fund raining activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Dementia Treatment Market dynamics, structure by identifying and analyzing the market segments and project the global market size.

Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Dementia Treatment Market.

Dementia Treatment Market Scope: Inquire before buying






Global Dementia Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 14.92 Bn.




Forecast Period 2023 to 2029 CAGR:
8.32%
Market Size in 2029:
US $ 26.11 Bn.




 Segments Covered:
by Drug Class
• Cholinergic/ Cholinesterase (ChE) Inhibitors
• Memantine
• Combined Drug
• Others




by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Sales






Dementia Treatment Market, by Region

● North America (United States, Canada and Mexico)
● Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
● Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
● Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
● South America (Brazil, Argentina, Columbia and Rest of South America)

Dementia Treatment Market, Key Players are:

• Pfizer, Inc.
• Merz Pharma GmbH & Co. KGaA.
• Novartis AG
• Allergan plc.
• Daiichi Sankyo Company, Ltd.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• Eisai Co., Ltd.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• Cipla Inc
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd
• Mylan N.V
• Dr. Reddy’s Laboratories Ltd
• Zydus Cadila
• Torrent Pharmaceuticals Ltd

Frequently Asked Questions:

1. Which region has the largest share in Dementia Treatment Market?
Ans: North America region holds the highest share in 2022.

2. What is the growth rate of Dementia Treatment Market?
Ans: The Dementia Treatment Market is growing at a CAGR of 8.32% during forecasting period 2023-2029.

3. What is scope of the Dementia Treatment market report?
Ans: Dementia Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Dementia Treatment market?
Ans: The important key players in the Dementia Treatment Market are – Pfizer, Inc., Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc., Daiichi Sankyo Company, Ltd., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., Cipla Inc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Mylan N.V, Dr. Reddy’s Laboratories Ltd, Zydus Cadila, and Torrent Pharmaceuticals Ltd.

5. What is the study period of this market?
Ans: The Dementia Treatment Market is studied from 2022 to 2029. 




Dementia Treatment Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Dementia Treatment Market Size, by Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Dementia Treatment Market Analysis and Forecast
6.1. Global Dementia Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Dementia Treatment Market Analysis and Forecast, By Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Dementia Treatment Market Value Share Analysis, By Drug Class
7.4. Global Dementia Treatment Market Size (US$ Mn) Forecast, By Drug Class
7.5. Global Dementia Treatment Market Analysis, By Drug Class
7.6. Global Dementia Treatment Market Attractiveness Analysis, By Drug Class
8. Global Dementia Treatment Market Analysis and Forecast, By Distribution Channel
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Dementia Treatment Market Value Share Analysis, By Distribution Channel
8.4. Global Dementia Treatment Market Size (US$ Mn) Forecast, By Distribution Channel
8.5. Global Dementia Treatment Market Analysis, By Distribution Channel
8.6. Global Dementia Treatment Market Attractiveness Analysis, By Distribution Channel
9. Global Dementia Treatment Market Analysis, by Region
9.1. Global Dementia Treatment Market Value Share Analysis, by Region
9.2. Global Dementia Treatment Market Size (US$ Mn) Forecast, by Region
9.3. Global Dementia Treatment Market Attractiveness Analysis, by Region
10. North America Dementia Treatment Market Analysis
10.1. Key Findings
10.2. North America Dementia Treatment Market Overview
10.3. North America Dementia Treatment Market Value Share Analysis, By Drug Class
10.4. North America Dementia Treatment Market Forecast, By Drug Class
10.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
10.4.2. Memantine
10.4.3. Combined Drug
10.4.4. Others
10.5. North America Dementia Treatment Market Value Share Analysis, By Distribution Channel
10.6. North America Dementia Treatment Market Forecast, By Distribution Channel
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Online Sales
10.7. North America Dementia Treatment Market Value Share Analysis, by Country
10.8. North America Dementia Treatment Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Dementia Treatment Market Analysis, by Country
10.10. U.S. Dementia Treatment Market Forecast, By Drug Class
10.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
10.10.2. Memantine
10.10.3. Combined Drug
10.10.4. Others
10.11. U.S. Dementia Treatment Market Forecast, By Distribution Channel
10.11.1. Hospital Pharmacies
10.11.2. Retail Pharmacies
10.11.3. Online Sales
10.12. Canada Dementia Treatment Market Forecast, By Drug Class
10.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
10.12.2. Memantine
10.12.3. Combined Drug
10.12.4. Others
10.13. Canada Dementia Treatment Market Forecast, By Distribution Channel
10.13.1. Hospital Pharmacies
10.13.2. Retail Pharmacies
10.13.3. Online Sales
10.14. North America Dementia Treatment Market Attractiveness Analysis
10.14.1. By Drug Class
10.14.2. By Distribution Channel
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Developments
11. Europe Dementia Treatment Market Analysis
11.1. Key Findings
11.2. Europe Dementia Treatment Market Overview
11.3. Europe Dementia Treatment Market Value Share Analysis, By Drug Class
11.4. Europe Dementia Treatment Market Forecast, By Drug Class
11.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.4.2. Memantine
11.4.3. Combined Drug
11.4.4. Others
11.5. Europe Dementia Treatment Market Value Share Analysis, By Distribution Channel
11.6. Europe Dementia Treatment Market Forecast, By Distribution Channel
11.6.1. Hospital Pharmacies
11.6.2. Retail Pharmacies
11.6.3. Online Sales
11.7. Europe Dementia Treatment Market Value Share Analysis, by Country
11.8. Europe Dementia Treatment Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Dementia Treatment Market Analysis, by Country
11.10. Germany Dementia Treatment Market Forecast, By Drug Class
11.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.10.2. Memantine
11.10.3. Combined Drug
11.10.4. Others
11.11. Germany Dementia Treatment Market Forecast, By Distribution Channel
11.11.1. Hospital Pharmacies
11.11.2. Retail Pharmacies
11.11.3. Online Sales
11.12. U.K. Dementia Treatment Market Forecast, By Drug Class
11.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.12.2. Memantine
11.12.3. Combined Drug
11.12.4. Others
11.13. U.K. Dementia Treatment Market Forecast, By Distribution Channel
11.13.1. Hospital Pharmacies
11.13.2. Retail Pharmacies
11.13.3. Online Sales
11.14. France Dementia Treatment Market Forecast, By Drug Class
11.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.14.2. Memantine
11.14.3. Combined Drug
11.14.4. Others
11.15. France Dementia Treatment Market Forecast, By Distribution Channel
11.15.1. Hospital Pharmacies
11.15.2. Retail Pharmacies
11.15.3. Online Sales
11.16. Italy Dementia Treatment Market Forecast, By Drug Class
11.16.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.16.2. Memantine
11.16.3. Combined Drug
11.16.4. Others
11.17. Italy Dementia Treatment Market Forecast, By Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Retail Pharmacies
11.17.3. Online Sales
11.18. Spain Dementia Treatment Market Forecast, By Drug Class
11.18.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.18.2. Memantine
11.18.3. Combined Drug
11.18.4. Others
11.19. Spain Dementia Treatment Market Forecast, By Distribution Channel
11.19.1. Hospital Pharmacies
11.19.2. Retail Pharmacies
11.19.3. Online Sales
11.20. Rest of Europe Dementia Treatment Market Forecast, By Drug Class
11.20.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.20.2. Memantine
11.20.3. Combined Drug
11.20.4. Others
11.21. Rest of Europe Dementia Treatment Market Forecast, By Distribution Channel
11.21.1. Hospital Pharmacies
11.21.2. Retail Pharmacies
11.21.3. Online Sales
11.22. Europe Dementia Treatment Market Attractiveness Analysis
11.22.1. By Drug Class
11.22.2. By Distribution Channel
11.23. PEST Analysis
11.24. Key Trends
11.25. Key Developments
12. Asia Pacific Dementia Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Dementia Treatment Market Overview
12.3. Asia Pacific Dementia Treatment Market Value Share Analysis, By Drug Class
12.4. Asia Pacific Dementia Treatment Market Forecast, By Drug Class
12.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.4.2. Memantine
12.4.3. Combined Drug
12.4.4. Others
12.5. Asia Pacific Dementia Treatment Market Value Share Analysis, By Distribution Channel
12.6. Asia Pacific Dementia Treatment Market Forecast, By Distribution Channel
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Sales
12.7. Asia Pacific Dementia Treatment Market Value Share Analysis, by Country
12.8. Asia Pacific Dementia Treatment Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Dementia Treatment Market Analysis, by Country
12.10. China Dementia Treatment Market Forecast, By Drug Class
12.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.10.2. Memantine
12.10.3. Combined Drug
12.10.4. Others
12.11. China Dementia Treatment Market Forecast, By Distribution Channel
12.11.1. Hospital Pharmacies
12.11.2. Retail Pharmacies
12.11.3. Online Sales
12.12. India Dementia Treatment Market Forecast, By Drug Class
12.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.12.2. Memantine
12.12.3. Combined Drug
12.12.4. Others
12.13. India Dementia Treatment Market Forecast, By Distribution Channel
12.13.1. Hospital Pharmacies
12.13.2. Retail Pharmacies
12.13.3. Online Sales
12.14. Japan Dementia Treatment Market Forecast, By Drug Class
12.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.14.2. Memantine
12.14.3. Combined Drug
12.14.4. Others
12.15. Japan Dementia Treatment Market Forecast, By Distribution Channel
12.15.1. Hospital Pharmacies
12.15.2. Retail Pharmacies
12.15.3. Online Sales
12.16. ASEAN Dementia Treatment Market Forecast, By Drug Class
12.16.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.16.2. Memantine
12.16.3. Combined Drug
12.16.4. Others
12.17. ASEAN Dementia Treatment Market Forecast, By Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Retail Pharmacies
12.17.3. Online Sales
12.18. Rest of Asia Pacific Dementia Treatment Market Forecast, By Drug Class
12.18.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.18.2. Memantine
12.18.3. Combined Drug
12.18.4. Others
12.19. Rest of Asia Pacific Dementia Treatment Market Forecast, By Distribution Channel
12.19.1. Hospital Pharmacies
12.19.2. Retail Pharmacies
12.19.3. Online Sales
12.20. Asia Pacific Dementia Treatment Market Attractiveness Analysis
12.20.1. By Drug Class
12.20.2. By Distribution Channel
12.21. PEST Analysis
12.22. Key Trends
12.23. Key Developments
13. Middle East & Africa Dementia Treatment Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Dementia Treatment Market Overview
13.3. Middle East & Africa Dementia Treatment Market Value Share Analysis, By Drug Class
13.4. Middle East & Africa Dementia Treatment Market Forecast, By Drug Class
13.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
13.4.2. Memantine
13.4.3. Combined Drug
13.4.4. Others
13.5. Middle East & Africa Dementia Treatment Market Value Share Analysis, By Distribution Channel
13.6. Middle East & Africa Dementia Treatment Market Forecast, By Distribution Channel
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Sales
13.7. Middle East & Africa Dementia Treatment Market Value Share Analysis, by Country
13.8. Middle East & Africa Dementia Treatment Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Dementia Treatment Market Analysis, by Country
13.10. GCC Dementia Treatment Market Forecast, By Drug Class
13.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
13.10.2. Memantine
13.10.3. Combined Drug
13.10.4. Others
13.11. GCC Dementia Treatment Market Forecast, By Distribution Channel
13.11.1. Hospital Pharmacies
13.11.2. Retail Pharmacies
13.11.3. Online Sales
13.12. South Africa Dementia Treatment Market Forecast, By Drug Class
13.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
13.12.2. Memantine
13.12.3. Combined Drug
13.12.4. Others
13.13. South Africa Dementia Treatment Market Forecast, By Distribution Channel
13.13.1. Hospital Pharmacies
13.13.2. Retail Pharmacies
13.13.3. Online Sales
13.14. Rest of Middle East & Africa Dementia Treatment Market Forecast, By Drug Class
13.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
13.14.2. Memantine
13.14.3. Combined Drug
13.14.4. Others
13.15. Rest of Middle East & Africa Dementia Treatment Market Forecast, By Distribution Channel
13.15.1. Hospital Pharmacies
13.15.2. Retail Pharmacies
13.15.3. Online Sales
13.16. Middle East & Africa Dementia Treatment Market Attractiveness Analysis
13.16.1. By Drug Class
13.16.2. By Distribution Channel
13.17. PEST Analysis
13.18. Key Trends
13.19. Key Developments
14. South America Dementia Treatment Market Analysis
14.1. Key Findings
14.2. South America Dementia Treatment Market Overview
14.3. South America Dementia Treatment Market Value Share Analysis, By Drug Class
14.4. South America Dementia Treatment Market Forecast, By Drug Class
14.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
14.4.2. Memantine
14.4.3. Combined Drug
14.4.4. Others
14.5. South America Dementia Treatment Market Value Share Analysis, By Distribution Channel
14.6. South America Dementia Treatment Market Forecast, By Distribution Channel
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Sales
14.7. South America Dementia Treatment Market Value Share Analysis, by Country
14.8. South America Dementia Treatment Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. South America Dementia Treatment Market Analysis, by Country
14.10. Brazil Dementia Treatment Market Forecast, By Drug Class
14.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
14.10.2. Memantine
14.10.3. Combined Drug
14.10.4. Others
14.11. Brazil Dementia Treatment Market Forecast, By Distribution Channel
14.11.1. Hospital Pharmacies
14.11.2. Retail Pharmacies
14.11.3. Online Sales
14.12. Mexico Dementia Treatment Market Forecast, By Drug Class
14.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
14.12.2. Memantine
14.12.3. Combined Drug
14.12.4. Others
14.13. Mexico Dementia Treatment Market Forecast, By Distribution Channel
14.13.1. Hospital Pharmacies
14.13.2. Retail Pharmacies
14.13.3. Online Sales
14.14. Rest of South America Dementia Treatment Market Forecast, By Drug Class
14.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
14.14.2. Memantine
14.14.3. Combined Drug
14.14.4. Others
14.15. Rest of South America Dementia Treatment Market Forecast, By Distribution Channel
14.15.1. Hospital Pharmacies
14.15.2. Retail Pharmacies
14.15.3. Online Sales
14.16. South America Dementia Treatment Market Attractiveness Analysis
14.16.1. By Drug Class
14.16.2. By Distribution Channel
14.17. PEST Analysis
14.18. Key Trends
14.19. Key Developments
15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Distribution Channels and R&D investment
15.2.2. New Treatment Center Launches and Treatment Center Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Distribution Channels
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration
15.3. Company Profiles: Key Players
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Treatment Center Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Merz Pharma GmbH & Co. KGaA.
15.3.3. Novartis AG
15.3.4. Allergan plc.
15.3.5. Daiichi Sankyo Company, Ltd.
15.3.6. Ono Pharmaceutical Co., Ltd.
15.3.7. Johnson & Johnson Services, Inc.
15.3.8. Eisai Co., Ltd.
15.3.9. H. Lundbeck A/S
15.3.10. F. Hoffmann-La Roche Ltd.
15.3.11. Cipla Inc.
15.3.12. Aurobindo Pharma.
15.3.13. Sun Pharmaceutical Industries Ltd.
15.3.14. Mylan N.V.
15.3.15. Dr. Reddy’s Laboratories Ltd.
15.3.16. Zydus Cadila.
15.3.17. Torrent Pharmaceuticals Ltd.

16. Primary Key Insights
  • INQUIRE BEFORE BUYING